Zoledronic Acid Effectively Prevents Cancer Treatment-Induced Bone Loss in Premenopausal Women Receiving Adjuvant Endocrine Therapy for Hormone-Responsive Breast Cancer: A Report From the Austrian Breast and Colorectal Cancer Study Group
J Clin Oncol Gnant et al. 24:820
Publisher’s Note
The March 1, 2007, article by Gnant et al titled, “Zoledronic Acid Effectively Prevents Cancer Treatment-Induced Bone Loss in Premenopausal Women Receiving Adjuvant Endocrine Therapy for Hormone-Responsive Breast Cancer: A Report From the Austrian Breast and Colorectal Cancer Study Group” (J Clin Oncol 10.1200/JCO.2005.02.7102) was published online on December 11, 2006, with incomplete legends for Figures 2 and 3.
The legend for Figure 2 should have read:
Percentage of patients with normal bone mineral density, osteopenia, or osteoporosis in the lumbar spine of those treated with anastrozole or tamoxifen ± zoledronic acid for 36 months. (A) Tamoxifen alone, (B) tamoxifen plus zoledronic acid, (C) anastrozole alone, and (D) anastrozole plus zoledronic acid. The change from baseline T score with anastrozole treatment across 36 months is significantly greater than that observed with tamoxifen (P < .0001). The addition of zoledronic acid significantly improves T score versus hormone therapy alone (P < .0001).
The legend for Figure 3 should have read:
Percentage of patients with normal bone mineral density, osteopenia, or osteoporosis in the trochanter of those treated with anastrozole or tamoxifen ± zoledronic acid for 36 months. (A) Tamoxifen alone, (B) tamoxifen plus zoledronic acid, (C) anastrozole alone, and (D) anastrozole plus zoledronic acid. The change from baseline T score with anastrozole treatment across 36 months is significantly greater than that observed with tamoxifen (P < .0001). The addition of zoledronic acid significantly improves T score versus hormone therapy alone (P < .0001).
These corrections have been made as of January 3, 2007.
|
